Clinical trial
Neo-Adjuvant Gemcitabine and Cisplatin in Treating Patients With Early Stage of…
NCT00191763 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191763 |
|---|---|
| Title | Neo-Adjuvant Gemcitabine and Cisplatin in Treating Patients With Early Stage of Non Small Cell Lung Cancer |
| Official title | Phase II Trial of Gemcitabine and Cisplatin as Neo-Adjuvant Chemotherapy for Operable Non-Small Cell Lung Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell-Lung Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, cisplatin |
| Enrollment | 52 |
| Start date | Nov 1, 2002 |
| Completion | Dec 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Nov 6, 2007 |
| Countries | Turkey (Türkiye) |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: